In May, the FDA approved atezolizumab in combination with bevacizumab for newly diagnosed patients with hepatocellular carcinoma.
Clinicians are using HoloLens to enhance the treatment of aortic aneurysms, ovarian cancer and even face transplant surgery. Now they’re adding treatment of liver tumors to the list.
HALT-HCC is practical, easy to implement and outperformed other selection criteria. It has the potential to become a new clinical tool that can lead to more efficient use of donated organs.
Cleveland Clinic surgeons have performed the Midwest’s first purely laparoscopic donor hepatectomy for living donor liver transplant, a technically demanding procedure that improves safety and shortens recovery times, possibly motivating more people to donate.
Statin use substantially reduces the risk of hepatocellular carcinoma and should be considered as a standard of care in patients at high risk for the disease, according to a Cleveland Clinic meta-analysis.
An innovative two-stage surgical treatment option that leverages the liver’s regenerative capacity is showing promise for some patients with previously unresectable liver metastases from colorectal cancer.
A multimodal approach of highly specialized radiation and chemotherapy followed by liver transplant can result in extremely promising outcomes in this difficult-to-manage disease.
A new study presented at ASCRS 2018 helps clinicians give rectal cancer patients treated with chemoradiation and surgery a clearer picture of what they can expect to plan their futures.
Developing disease-based programs and working on shared initiatives has allowed us to achieve successful clinical integration.
Study reveals that the successful downstaging of advanced HCC via locoregional therapy prior to transplant yields 5-year survival rate of 60 percent. Two liver experts explain the impact on patients and the transplant community.